FindTrial
Sign In

A clinical trial of TATC/HT/001 as a treatment modality in hyperthyroidism.

A clinical trial to evaluate the safety and efficacy of TATC/HT/001 as a treatment modality in hyperthyroidism. - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/03/050527
Enrollment
30
Registered
2023-03-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E059- Thyrotoxicosis, unspecified

Interventions

Intervention1: TATC/HT/001: 1 capsule Twice a day orally for 6 months Control Intervention1: Nil: Nil Control Intervention2: Nil: Nil

Sponsors

Ayurgenics Ayurveda Private Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult males or females,greater than or equal to 18yr age with a diagnosis of Gravesâ??disease ( Hyperthyroidism) 2.Gravesâ?? disease (Hyperthyroidism) defined as raised T4 and/or T3 3.low TSH with or without hypermetabolic symptoms

Exclusion criteria

Exclusion criteria: Pregnancy/planning pregnancy in next 01 yr, use of Antithyroid drugs, iodine containing drugs, Multinodular goiter, thyroid malignancy/suspicious nodules, significant eye disease, Refusal to give consent

Design outcomes

Primary

MeasureTime frame
Changes in TFT Changes in symptoms Changes in BMRTimepoint: Baseline to end of study ie 6 months—

Secondary

MeasureTime frame
Reduction in conventional medicine dosage Changes in Quality of life Tolerability Adverse eventsTimepoint: Baseline to end of study ie 6 months—

Countries

India

Contacts

Public ContactDr Vikrant Patil

The Ayurvedic Thyroid Clinic

sushmalpatil85@gmail.com9764226600

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026